Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijbiomac.2020.06.213 http://scihub22266oqcxt.onion/10.1016/j.ijbiomac.2020.06.213 32599237!7319648!32599237     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Biol+Macromol 2020 ; 162 (ä): 820-837 Nephropedia Template TP {{tp|p=32599237|t=2020. Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach |pdf=|usr=}}{{32599237}} gab.com Text Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach JO: Int J Biol Macromol http://www.kidney.de/pget.php?&tw=1&pmid=32599237 #FOAvip SARS-CoV-2 is the deadly virus behind COVID-19, the disease that went on to ravage the world and caused the biggest pandemic 21st century has witnessed so far. On the face of ongoing death and destruction, the urgent need for the discovery of a vaccine against the virus is paramount. This study resorted to the emerging discipline of immunoinformatics in order to design a multi-epitope mRNA vaccine against the spike glycoprotein of SARS-CoV-2. Various immunoinformatics tools were utilized to predict T and B lymphocyte epitopes. The epitopes were channeled through a filtering pipeline comprised of antigenicity, toxicity, allergenicity, and cytokine inducibility evaluation with the goal of selecting epitopes capable of generating both T and B cell-mediated immune responses. Molecular docking simulation between the epitopes and their corresponding MHC molecules was carried out. 13 epitopes, a highly immunogenic adjuvant, elements for proper sub-cellular trafficking, a secretion booster, and appropriate linkers were combined for constructing the vaccine. The vaccine was found to be antigenic, almost neutral at physiological pH, non-toxic, non-allergenic, capable of generating a robust immune response and had a decent worldwide population coverage. Based on these parameters, this design can be considered a promising choice for a vaccine against SARS-CoV-2. Twit Text FOAVip Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach ????Int J Biol Macromol http://www.kidney.de/pget.php?&tw=1&pmid=32599237 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32599237 #FOAvip English Wikipedia <ref>{{Cite pmid|32599237}}</ref> Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach #MMPMID32599237 Ahammad I; Lira SS Int J Biol Macromol 2020[Nov]; 162 (ä): 820-837 PMID32599237show ga SARS-CoV-2 is the deadly virus behind COVID-19, the disease that went on to ravage the world and caused the biggest pandemic 21st century has witnessed so far. On the face of ongoing death and destruction, the urgent need for the discovery of a vaccine against the virus is paramount. This study resorted to the emerging discipline of immunoinformatics in order to design a multi-epitope mRNA vaccine against the spike glycoprotein of SARS-CoV-2. Various immunoinformatics tools were utilized to predict T and B lymphocyte epitopes. The epitopes were channeled through a filtering pipeline comprised of antigenicity, toxicity, allergenicity, and cytokine inducibility evaluation with the goal of selecting epitopes capable of generating both T and B cell-mediated immune responses. Molecular docking simulation between the epitopes and their corresponding MHC molecules was carried out. 13 epitopes, a highly immunogenic adjuvant, elements for proper sub-cellular trafficking, a secretion booster, and appropriate linkers were combined for constructing the vaccine. The vaccine was found to be antigenic, almost neutral at physiological pH, non-toxic, non-allergenic, capable of generating a robust immune response and had a decent worldwide population coverage. Based on these parameters, this design can be considered a promising choice for a vaccine against SARS-CoV-2. |Betacoronavirus/immunology[MESH] |COVID-19[MESH] |COVID-19 Vaccines[MESH] |Coronavirus Infections/genetics/immunology/*prevention & control/virology[MESH] |Drug Design[MESH] |Epitopes, B-Lymphocyte/chemistry/immunology[MESH] |Epitopes, T-Lymphocyte/chemistry/immunology[MESH] |Humans[MESH] |Immunogenicity, Vaccine[MESH] |Molecular Docking Simulation[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/immunology/*prevention & control/virology[MESH] |RNA, Messenger/*immunology[MESH] |SARS-CoV-2[MESH] |Sequence Analysis, Protein[MESH] |Spike Glycoprotein, Coronavirus/chemistry/immunology[MESH] |Vaccines, Synthetic/chemistry/genetics/immunology[MESH]Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatic(epmc).pdf DeepDyve Pubget Overpricing